Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qi Rong Fuzheng oral liquid (also known as Shadu Cao oral liquid) is a traditional Chinese medicine (TCM) formulation developed by the Jingning She Autonomous County Natural New Special Medicine Research Institute. It is currently being investigated in exploratory clinical trials as an adjunctive therapy for adult HIV/AIDS patients. The treatment is specifically targeted at patients who have achieved stable viral suppression through long-term highly active antiretroviral therapy (HAART) but continue to exhibit moderate CD4+ T-cell counts, indicating incomplete immune reconstitution. The formulation is derived from botanical sources, including *Sarcopyramis nepalensis* (Shadu Cao), and is intended to "fuzheng" (strengthen the body's resistance) by modulating the immune system and supporting the recovery of T-lymphocyte populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qi Rong Fuzheng oral liquid.